Valeant’s Ongoing Challenges – Seeking Alpha
CBC.ca |
Valeant's Ongoing Challenges
Seeking Alpha Tuesday, Valeant lowered sales expectations for this year, projected a mildly lower tax rate and projected inadequate normalized cash flow. Monday, the company reported that an important glaucoma NDA did not receive its expected FDA approval, harming … Valeant Isn't Out of Trouble Yet, Debt Remains Difficult to CurbTheStreet.com Valeant's Guidance Gymnastics Point to a CutBloomberg Valeant Pharmaceuticals: Bears Will Be BearsBarron’s MarketWatch –CNBC –StreetInsider.com –Fox Business all 182 news articles » |